Video Experimental Relacionado
Updated: Jun 9, 2026
10:05
Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
Published on: July 7, 2016
Interacciones entre medicamentos en cardiología y oncología: una declaración científica de la Asociación Americana
Circulation
|March 7, 2022
Resumen
Las interacciones farmacológicas son críticas en la cardio-oncología debido a los tratamientos complejos. Comprender y controlar estas interacciones, ya sean farmacocinéticas o farmacodinámicas, es clave para garantizar la seguridad del paciente y la eficacia del tratamiento.
Área de la Ciencia:
- Cardio-oncología
- Farmacología clínica
- En el campo de la oncología
Sus antecedentes:
- Las interacciones farmacológicas presentan riesgos significativos en el campo de la cardiopatía oncológica debido a los complejos perfiles y terapias de los pacientes.
- Tanto los tratamientos cardiovasculares como los de cáncer conllevan riesgos inherentes que pueden ser exacerbados por las interacciones medicamentosas.
Objetivo del estudio:
- Proporcionar a los médicos una visión general de las interacciones entre fármacos en el ámbito de la cardioncología.
- Discutir las interacciones farmacodinámicas y farmacocinéticas relevantes para los medicamentos cardiovasculares y para el cáncer.
Principales métodos:
- Revisión de la literatura existente sobre las interacciones farmacológicas en cardio-oncología.
- Análisis de medicamentos cardiovasculares y contra el cáncer comunes y sus posibles interacciones.
Principales resultados:
- Las interacciones farmacológicas pueden ser perjudiciales, reduciendo la eficacia o la seguridad de las terapias contra el cáncer o cardiovasculares.
- La comprensión de los mecanismos de interacción (farmacocinética y farmacodinámica) es crucial.
Conclusiones:
- Los médicos deben estar al tanto de las posibles interacciones entre fármacos en el ámbito de la cardio-oncología.
- Las estrategias de mitigación incluyen reconocimiento, medicamentos alternativos y monitoreo cuidadoso.
Videos de Conceptos Relacionados
01:26Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
01:22Heart Failure Drugs: Diuretics
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However, frequent irregular...
01:26FDA Approved Drugs: Changes to Approved Drugs
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...